Intermune strikes Italian risk-sharing Esbriet deal
This article was originally published in Scrip
A risk-sharing deal with payers in Italy has helped Intermune secure reimbursement for its orphan drug Esbriet (pirfenidone) for treating idiopathic pulmonary fibrosis.
You may also be interested in...
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.
Brazil’s pharmaceutical industry has welcomed the election of medicines regulator ANVISA to the management committee of the International Council for Harmonization.